Most cited papers from Hôpital Saint-André

Hôpital Saint-André

What are the most cited papers from Hôpital Saint-André?

The most cited paper from Hôpital Saint-André is "Sorafenib in Advanced Hepatocellular Carcinoma" (Josep Maria Llovet et al., 2008), with 13,116 citations. Next come "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation" (7,801) and "Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma" (5,972).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 406 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Sorafenib in Advanced Hepatocellular Carcinoma Josep Maria Llovet et al. · New England Journal of Medicine Open access	23 Jul 2008	13,116
2	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman et al. · New England Journal of Medicine Open access	5 Jun 2011	7,801
3	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access	25 Sep 2015	5,972
4	Nivolumab in Previously Untreated Melanoma without BRAF Mutation Caroline Robert et al. · New England Journal of Medicine Open access	16 Nov 2014	5,431
5	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access	21 Mar 2018	4,756
6	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Robert John Motzer, Bernard J. Escudier, Stéphane Marie. Oudard et al. · The Lancet	23 Jul 2008	3,036
7	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Axel Hauschild et al. · The Lancet	25 Jun 2012	3,009
8	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine	9 Feb 2011	2,567
9	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Bernard J. Escudier, Anna Pluzanska, P. Koralewski et al. · The Lancet	Dec 2007	2,234
10	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets Kornelius Schulze et al. · Nature Genetics Open access	30 Mar 2015	1,896
11	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma Georgina Venetia Long et al. · New England Journal of Medicine Open access	10 Sep 2017	1,501
12	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Georgina Venetia Long et al. · The Lancet	31 May 2015	1,419
13	Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system Monique Trojani, G Contesso, Jean‐Michel Coindre et al. · International Journal of Cancer	15 Jan 1984	1,327
14	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma David F. McDermott et al. · Nature Medicine Open access	29 May 2018	1,280
15	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Andrea Wang‐Gillam et al. · The Lancet	29 Nov 2015	1,232
16	Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I Andreas Wollenberg, S. Barbarot, Thomas R.M. Bieber et al. · Journal of the European Academy of Dermatology and Venereology Open access	20 Apr 2018	1,191
17	Pitfalls of Liver Stiffness Measurement: A 5-Year Prospective Study of 13,369 Examinations Laurent Castéra, Juliette Foucher, Pierre–Henri Bernard et al. · Hepatology Open access	9 Nov 2009	1,164
18	Phase 3 trial of everolimus for metastatic renal cell carcinoma Robert John Motzer, Bernard J. Escudier, Stéphane Marie. Oudard et al. · Cancer	14 Jun 2010	1,148
19	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Reinhard Dummer, Paolo A. Ascierto, Helen J Gogas et al. · The Lancet Oncology Open access	21 Mar 2018	1,040
20	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Brian I. Rini et al. · The Lancet	9 May 2019	1,029
21	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial Paolo A. Ascierto et al. · The Lancet Oncology	30 Jul 2016	1,027
22	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Grant A. McArthur et al. · The Lancet Oncology Open access	6 Feb 2014	988
23	Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria Christophe Duvoux et al. · Gastroenterology Open access	29 Jun 2012	966
24	A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments Jérôme Stirnemann, Nadia Belmatoug, Fabrice Camou et al. · International Journal of Molecular Sciences Open access	17 Feb 2017	887
25	Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome Stéphane Chavanas, Christine Bodemer, Ariane Rochat et al. · Nature Genetics	Jun 2000	853
26	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Andrew Xiuxuan Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology Open access	18 Jun 2015	850
27	Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Sorèze 2009 Vinzenz Oji et al. · Journal of the American Academy of Dermatology	21 Jul 2010	805
28	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Toni K. Choueiri et al. · New England Journal of Medicine Open access	18 Aug 2021	792
29	Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC Jessica Zucman‐Rossi et al. · Hepatology Open access	22 Feb 2006	764
30	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Gwénaëlle Gravis et al. · The Lancet Oncology	8 Jan 2013	747
31	Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers Tania Roskams et al. · Hepatology Open access	30 Apr 2004	736
32	Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II Andreas Wollenberg, S. Barbarot, Thomas R.M. Bieber et al. · Journal of the European Academy of Dermatology and Venereology Open access	28 May 2018	692
33	MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations Yannick Ladeiro, Gabrielle Couchy, Charles Paul Balabaud et al. · Hepatology Open access	Feb 2008	686
34	Guidelines for treatment of atopic eczema (atopic dermatitis) Part I Johannes Ring et al. · Journal of the European Academy of Dermatology and Venereology	18 Jul 2012	684
35	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial David Laharie et al. · The Lancet	25 Oct 2012	653
36	Elimination of atrioventricular nodal reentrant tachycardia using discrete slow potentials to guide application of radiofrequency energy. Michel Haı̈ssaguerre, Fiorenzo Gaïta, Bruno Fischer et al. · Circulation	Jun 1992	609
37	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Manish R. Patel, John Allan Ellerton, Jeffrey R. Infante et al. · The Lancet Oncology Open access	5 Dec 2017	591
38	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial Reinhard Dummer, Paolo A. Ascierto, Helen J Gogas et al. · The Lancet Oncology	12 Sep 2018	589
39	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Thomas B. Powles et al. · Nature Medicine Open access	Nov 2019	585
40	Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial Guillaume Portier, Dominique Elias, Olivier Bouché et al. · Journal of Clinical Oncology	30 Oct 2006	583
41	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib Andrew Xiuxuan Zhu, Masatoshi Kudo, Eric Assénat et al. · JAMA Open access	2 Jul 2014	577
42	Propranolol for Severe Infantile Hemangiomas: Follow-Up Report Véronique Sans, Eric Dumas de la Roque, Jérôme Berge et al. · PEDIATRICS	10 Aug 2009	572
43	Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Tom Powles, Joaquim Bellmunt, Éva Compérat et al. · Annals of Oncology Open access	30 Nov 2021	552
44	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications Pierre Nahon et al. · Gastroenterology Open access	16 Sep 2016	540
45	Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial Michel Azizi, Marc R. Sapoval, Philippe Gosse et al. · The Lancet	25 Jan 2015	519
46	The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force Alain Taı̈eb, Mauro Picardo, on behalf of the other VETF members · Pigment Cell Research	11 Jan 2007	514
47	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial Reinhard Dummer et al. · The Lancet Oncology Open access	8 Mar 2017	498
48	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas Jean‐Charles Nault, Shalini Datta, Sandrine Imbeaud et al. · Nature Genetics	24 Aug 2015	497
49	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours Sandra Rebouissou, Mohamed Amessou, Gabrielle Couchy et al. · Nature Open access	19 Nov 2008	476
50	Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Francesco Locatelli, R.L. Pisoni, Christian Combe et al. · Nephrology Dialysis Transplantation	11 Dec 2003	472

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.